About this trial
Intravitreal dyes are intended to make the surgical extraction of the Internal limiting membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is ongoing. The most commonly used vital dye is Indocyanine green (ICG), although it is not approved for intravitreal use and has been associated with ocular toxicity. The reason for its continued popularity seems to be that it stains the ILM better than the approved and less toxic alternative substances Brilliant Blue G (BBG) and Trypan blue (TB). According to anecdotal reports from surgeons, another reason for ICGs popularity may be the fact that it seems to make ILM removal easier. Ultimately, the intention of the investigators research is to identify possible modifications to existing dyes to reach improved intraoperative dye utility combined with a favorable safety profile.
Protocol was amended and approved concerning additional use of basal membrane of deceased donors.
Eligibility criteria
Qualifiers
Over 18 Years of age
No other chromovitrectomy in previous 6 months
Only one of three vitaly dyes used intraoperatively (BBG, ICG or TB)
Disqualifiers
Previous chromovitrectomy during last 6 months
Pregnant patients
Patients under 18 years of age
Trial design
Treatments tested in this trial
- Use of intraoperative filters in vitrectomy
Treatment groups
Sponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
University of the Italian Switzerland
Collaborator
Clinical Trial Unit, University Hospital Basel, Switzerland
Collaborator
General Hospital Linz
Collaborator
Oftacentro SA
Collaborator